Status:
COMPLETED
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
Lead Sponsor:
AstraZeneca
Conditions:
Perception of Physicians & Patients of AMD
Eligibility:
All Genders
12+ years
Brief Summary
This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within th...
Eligibility Criteria
Inclusion
- Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent
- Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).
Exclusion
- Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1
- Upper Respiratory Tract Infection in the previous four weeks
- Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study.
- Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate.
- Previous enrollment in a clinical study
- Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT00812682
Start Date
September 1 2006
End Date
August 1 2007
Last Update
January 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.